World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
53836
World Ranking
8752
National Ranking
4512

Eric K. Rowinsky publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric K. Rowinsky sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 421 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eric K. Rowinsky D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric K. Rowinsky sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eric K. Rowinsky is affiliated with Eli Lilly in the United States and has contributed extensively to research in medicine, with a focus on oncology and related subfields. Their work spans various aspects of cancer research, immunology, biotechnology, and genetics, with a significant emphasis on CAR-T cell therapy and virus-based gene therapies.

Rowinsky's research portfolio includes 31 publications in medicine and 17 in biochemistry, genetics, and molecular biology. Among the primary subfields addressed are oncology, immunology, biotechnology, genetics, and radiology, nuclear medicine, and imaging. The scientist's main topics of investigation cover:

  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • Virus-based gene therapy research
  • Biosimilars and Bioanalytical Methods
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Immunotherapy and Biomarkers
  • Immune cells in cancer

Rowinsky has published in several scientific venues, with the most frequent being the Journal of Clinical Oncology (9 papers), followed by Cancer Research (5), Regular and Young Investigator Award Abstracts (2), Investigational New Drugs (1), and The Lancet Oncology (1).

Notable recent papers include:

  • "Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma," 2020, Investigational New Drugs
  • "LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study," 2024, The Lancet Oncology
  • "Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer," 2024, JAMA Oncology
  • "A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer," 2022, Journal of Clinical Oncology
  • "A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report," 2020, Journal of Clinical Oncology

The scientist collaborates frequently with researchers such as Marwan Fakih, Jessica Wenthe, Emma Eriksson, Gustav Ullenhag, and Dongqi Chen, each representing recurrent contributions to related research themes and clinical studies.

Best Publications

  • Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner;Paul M. Harari;Jordi Giralt;Nozar Azarnia

  • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

    James A Bonner;Paul M Harari;Jordi Giralt;Roger B Cohen

  • Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

    William P. McGuire;Eric K. Rowinsky;Neil B. Rosenshein;Francis C. Grumbine

  • Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

    Román Pérez-Soler;Abraham Chachoua;Lisa A. Hammond;Eric K. Rowinsky

  • Taxol: A Novel Investigational Antimicrotubule Agent

    Eric K. Rowinsky;Lorranie A. Cazenave;Ross C. Donehower

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

    Malcolm R Ranson;Lisa A Hammond;David R Ferry;Mark Kris

  • Clinical toxicities encountered with paclitaxel (Taxol)

    Rowinsky Ek;Eisenhauer Ea;Chaudhry;Arbuck Sg

  • Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

    George W. Sledge;Donna Neuberg;Patricia Bernardo;James N. Ingle

  • Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

    Philip Bonomi;KyungMann Kim;Diane Fairclough;David Cella

  • The Current Status of Camptothecin Analogues as Antitumor Agents

    William J. Slichenmyer;Eric K. Rowinsky;Ross C. Donehower;Scott H. Kaufmann

  • The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

    Manuel Hidalgo;Eric K Rowinsky

  • Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

    Jennifer L. Spratlin;Roger B. Cohen;Matthew Eadens;Lia Gore

  • Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

    Eric K. Rowinsky;Jolene J. Windle;Daniel D. Von Hoff

  • Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

    Heinz Josef Lenz;Eric Van Cutsem;Shirin Khambata-Ford;Robert J. Mayer

  • Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study

    E K Rowinsky;M R Gilbert;W P McGuire;D A Noe

  • Taxol: the first of the taxanes, an important new class of antitumor agents.

    Eric K. Rowinsky;Eric K. Rowinsky;Nicole Onetto;Nicole Onetto;Renzo M. Canetta;Renzo M. Canetta;Susan G. Arbuck;Susan G. Arbuck

  • Cardiac disturbances during the administration of taxol.

    Eric K. Rowinsky;William P. McGuire;Thomas Guarnieri;Jason S. Fisherman

  • The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

    Eric K. Rowinsky;Ross C. Donehower

Frequent Co-Authors

Ross C. Donehower
Ross C. Donehower Johns Hopkins University
David S. Ettinger
David S. Ettinger Johns Hopkins University
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Arlene A. Forastiere
Arlene A. Forastiere Johns Hopkins University
Manuel Hidalgo
Manuel Hidalgo Cornell University
Amita Patnaik
Amita Patnaik University of Chicago
Richard J. Jones
Richard J. Jones Johns Hopkins University
Alex A. Adjei
Alex A. Adjei Cleveland Clinic
Yung-Chi Cheng
Yung-Chi Cheng Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always require pursuing a traditional MD. There are many alternative pathways and online degrees in healthcare offering flexibility, diverse roles, and quicker entry into the workforce.

Many students begin their medical careers through direct entry nursing programs that allow individuals with a bachelor’s degree (in any field) to transition into nursing quickly. For those interested in nursing but looking for less strenuous entry requirements, an lpn program without teas test can be a good option, bypassing standardized entrance exams.

Non-clinical healthcare roles are always in demand. Earning a degree from one of the best online medical billing and coding schools that accept fafsa allows students to work in the administrative backbone of healthcare, often fully online and with financial aid options. Similarly, moving into leadership roles is possible with healthcare administration degree programs available online, designed for both new entrants and working professionals seeking advancement.

These pathways provide practical alternatives for those seeking fulfilling healthcare careers without the lengthy commitment of medical school.

Best Scientists Citing Eric K. Rowinsky

Trending Scientists

Recently Published Articles